On October 4, 2022 Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, reported the appointment of Dr Giovanni Selvaggi as Chief Medical Officer (CMO) (Press release, Imugene, OCT 4, 2022, View Source [SID1234621683]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Selvaggi is a pulmonologist, trained in thoracic malignancies management with a focus on lung cancers and mesothelioma. He brings more than a decade of experience in the pharmaceutical industry which has seen him in clinical development focused roles of increasing responsibility with GlaxoSmithKline (GSK), Novartis Oncology and Bristol Myers Squibb.
Dr Selvaggi held a pivotal role in Novartis successful development and approval of ceritinib (or Zykadia, targeting non-small cell lung cancer/NSCLC) and was part of the immunotherapy team at Bristol Myers Squibb that led to the approval of nivolumab (Opdivo) in third line small cell lung cancer.
His most recent role with US oncology company Xcovery Holdings Inc saw Dr Selvaggi progress from CMO to be appointed CEO and CMO early in 2021. Prior to this Dr Selvaggi also served as Vice President, Clinical Development at Oncolytics Biotech in Canada. Additionally, he has been a well-regarded presenter at major international medical conferences as well as having authored numerous peer reviewed articles in major oncology journals.
Prior to entering the pharmaceutical sector Dr Selvaggi was as an attending physician at Thoracic Oncology-San Luigi Hospital in Turin, Italy. This included being an investigator on various oncology clinical trials.
Dr Selvaggi studied at the Medical School at the University of Torino in Italy, where he also completed his Residency in Respiratory Medicine at the Postgraduate Medical School.
Imugene’s M.D. & CEO, Ms Leslie Chong said: "We are delighted to welcome Dr Selvaggi to the Imugene team as our clinical development activities grow in both number and importance. He brings big pharma prowess that we expect to be very valuable, as well as having an excellent understanding of the experience of the institutions and investigators typically associated with drug development. He’s another excellent appointment to the world-class team we’re building."